CALPAIN

KNOCKDOWN THERAPY
  ◊ In Vivo Calpain Knockdown Using Delivery of siRNA

CANCER

CANCER THERAPY
  ◊ Monoclonal antibody linked to a radionuclide
  ◊ Targeting protein kinases
  ◊ Precision Targeted Therapy With BLU-667 for RET
  ◊ Camouflaged nanoparticles used to deliver killer protein to cancer
  ◊ Cancer therapy with a CRISPR-assisted telomerase-activating gene expression system
  ◊ Small molecule DNA-PK inhibitors as potential cancer therapy
  ◊ Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy


  ◊ Interleukins and interferons in mesenchymal stromal stem cell-based gene therapy of cancer

  ◊ Nanoliposomes as nonviral vectors in cancer gene therapy

CRISPR/Cas9 GENE EDITING
  ◊ CRISPR/Cas9 gene editing technique in the study of cancer treatment
  ◊ Cancer gene therapy by NF-kB-activated cancer cell-specific expression
  ◊CRISPR/Cas6 T Cell-Based Immunotherapy of Cancer
  ◊CRISPR-Cas9 gene-editing technology in cancer research

PERSONALIZED CANCER THERAPY
  ◊ MicroRNAs

CANCER T CELL THERAPY
  ◊ Multiple pathways underlying antitumor function of TCR- and CD8αβ-engineered human CD4+ T cells
  ◊CRISPR/Cas6 T cell immuotherapy of cancer
  ◊CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy

SUPPRESSION TUMOR GROWTH
  ◊ Carbohydrate-binding proteins
  ◊ Bevacizumab
  ◊ Pemetrexed disodium
  ◊ Small-molecule antagonists of MDM2
  ◊ Notch signalling
  ◊ TGF-beta signalling inhibitors

HEDGEHOG'S Pathway
  ◊ HhAntag CANCER OF BREAST

ErbB SIGNALLING
  ◊ Therapy with trastuzumab

TERAPEUTIC APPROCHES
  ◊ Drugs

CANCER OF COLON

COLORECTAL CANCER
  ◊ Oxaliplatin

CAR T-CELLS

GENE EDITING
  ◊ Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
  ◊ Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing

CARDIOVASCULAR DISEASES

GENE THERAPY
  ◊ Genome-editing therapies for cardiovascular diseases
  ◊ Gene Therapy for Cardiovascular Disease
  ◊ Gene Modulation with CRISPR-based Tools in Human iPSC-Cardiomyocytes
  ◊ How do phytocannabinoids affect cardiovascular health
  ◊ Applications of Gene Therapy in Cardiomyopathies
  ◊Targeted genetic therapies for inherited disorders that affect both cardiac and skeletal muscle
  ◊Gene Therapy for Hypertension, Atherosclerosis, and Familial Hypercholesterolemia
  ◊Gene Gene Therapy in Cardiovascular Disease: Recent Advances and Future Directions in Science

CARTILAGE REPAIR

GENE THERAPY
  ◊ The Role of Gene Therapy in Cartilage Repair
  ◊ “Genetic scissors” CRISPR/Cas9 genome editing cutting-edge biocarrier technology for bone and cartilage repair

CELL-BASED THERAPEUTICS

GENE THERAPY
  ◊ Engineering the next generation of cell-based therapeutics

CIRCULAR DNA SINGLE-STRANDED

NEW THERAPY
  ◊Single-stranded circular DNA theranostics

CORONARY OBSTRUCTION

NEW THERAPY
  ◊ Transcatheter Laceration of Aortic Leaflets

GENE THERAPY
  ◊ modified mRNA encoding vesicular stomatitis virus matrix protein for colon cancer gene therapy

PREVENTION
  ◊ Conjugated linoleic acid (CLA)

CANNABINOID SYSTEM

DRUGs
  ◊ Therapy with cannabinoids

CARDIAC ARRHYTHMIA

PROTECTION
  ◊ Calstabin2

CARDIOMYOPATHIES

GENE THERAPY
  ◊ In Vivo and Ex Vivo Gene Therapy Cardiomyopathies

CARDIOVASCULAR DISEASES

CORONARY ATHEROSCLEROSIS THERAPY
  ◊ Heme oxygenase-1-mediated release of carbon monoxide
  ◊ Statins

  ◊ Urine-Derived Induced Pluripotent Stem Cells in Cardiovascular Disease

ISCHAEMIA
  ◊ Therapeutic angiogenesis
  ◊ Neovascularization with Thymosin beta4

PROTECTION
  ◊ Glycogen synthase kinase-3β

THERAPY
  ◊ Combinations of Drugs
  ◊ Combination therapy with VEGF and Ang-1
  ◊ Cultivation of myocytes
  ◊ Effects of HDL (high-density lipoprotein)

CELIAC DISEASE

DETOCSIFICATION OF GLUTEN
  ◊ Therapy

CELL THERAPY

HUMAN PLURIPOTENT STEM CELL
  ◊Improving the safety using genome-edited orthogonal safeguards

CENTRONUCLEAR MYOPATHY

CRISPR/Cas9 CORRECTION
  ◊ Allele-Specific CRISPR/Cas9 Correction of a Heterozygous DNM2 Mutation Rescues Centronuclear Myopathy

CEROID LIPOFUSCINOSIS-CLN2 DISEASE

GENE THERAPY
  ◊ Gene Therapy Makes Promising Strides in Lysosomal Storage Diseases

CHARCOT–MARIE–TOOTH DISEASE

PATHWAYS TO MOLECULAR BASED THERAPIES
  ◊ Advances

CHITOSAN

VECTOR FOR GENE THERAPY
  ◊ Developments and challenges

CHROMODOMAIN HELICASE DNA-BINDING RELATED DISORDERS

THERAPIES
  ◊ A roadmap to cure CHD2-related disorders

CHOLESTEROLEMIA

CHOLESTEROL-LOWERING DRUG
  ◊ Berberine

REDUCTION ABSORPTION
  ◊ PPARδ activated agonist GW610742

GENE THERAPY
  ◊ Hypercholesterinemia; Therapeutic base editing in the adult liver PCSK9

CHRONIC LYMPHOCYTIC LEUKEMIA

PERSONALIZED CELL THERAPY
  ◊ Complete remission CHRONIC KYDNEY DISEASE

THERAPY
  ◊ Sirtuin 6 and renal injury CHRONIC MIGRAINE

DRUG THERAPY
  ◊ Fremanezumab for the Preventive Treatment

CENTRAL NERVOUS SYSTEM ANOMALIES

GENE THERAPY
  ◊ Non-Viral Delivery of RNA Gene Therapy to the Central Nervous System

COCAINE SEEKING

ATTENUATE
  ◊ Glucagon-like peptide-1 receptor activation attenuates cocaine seeking in rats

CODON-OPTIMIZATION

GENE THERAPY
  ◊ Codon-optimization in gene therapy: promises, prospects

COLON CANCER

GENE TNERAPY
  ◊ Delivery IL-22BP gene by cationic micelle for colon cancer gene therapy

COLORECTAL CANCER
  ◊ A Duplex CRISPR-Cas9 Colorectal Cancer Gene Therapy
  ◊ Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment

COLOR VISION DEFICIENCY

GENE TNERAPY
  ◊ Gene therapy in color vision deficiency
  ◊ Gene therapy in color vision deficiency

CONGENITAL DYSERYTHROPOIETIC ANEMIAS

GENE THERAPY
  ◊ Lentiviral Gene Therapy for the Correction of Congenital Dyserythropoietic Anemia Type II

CONGENITAL MUSCULAR DYSTROPHIES

BYPASS α-DYSTROGLYCAN GLYCOSYLATION DEFECTS
  ◊ LARGE

CONVERSION of BASES DNA

CONVERSION of CITOSIN IN URACIL
  ◊ CRISPR/Cas Technology

CORNEA

THERAPY APPROACHES
  ◊ Transcatheter Laceration of Aortic Leaflets

CORONARY OBSTRUCTION

NEW THERAPY
  ◊ Transcatheter Laceration of Aortic Leaflets

CORONOVIRUS

THERAPY
  ◊ Gene Therapy
  ◊ Gene Therapy and Gene editing and RNAi approaches

COVID-19

THERAPY
  ◊ Gene Therapy
  ◊ HSC Gene Therapy

CRISPR/Cas THERAPY CAS NUCLEASE

ACTIVATION MECHANISMS OF Cas9
  ◊ R-loop formation and conformational activation mechanisms of Cas9

Cas12 NUCLEASES
  ◊ Research progress on nucleic acid detection and genome editing of CRISPR/Cas12 system

Cas13 NUCLEASES
  ◊ The Wonderfully Shrunken Cas13

GENE THERAPY
  ◊ Efficient CRISPR editing with a hypercompact Cas12f1 and engineered guide RNAs delivered by adeno-associated virus
  ◊ UK first to approve CRISPR treatment for diseases
  ◊ Recent Advances in Genome-Engineering Strategies
  ◊ CRISPR Gene Editing: Cas9 and Beyond
  ◊ CRISPR Gene Editing: Cas9 and Beyond

OFF-TARGET CLEAVAGE ASSAYS
  ◊ crisprSQL: a novel database platform for CRISPR/Cas off-target cleavage assays
  ◊ Precise CRISPR-Cas–mediated gene repair with minimal off-target and unintended on-target mutations in human hematopoietic stem cells
  ◊ Off-target effects in CRISPR/Cas9 gene editing

HOMOLOGY DIRECTED CORRECTION
  ◊ Homology directed correction, a new pathway model for point mutation repair catalyzed by CRISPR-Ca

CONTROL
  ◊ Molecular Glue 'Shreds' Cas9 and Enables a New Form of CRISPR Control

COVID-19

HEMATOLOGICAL COMPLICATIONS
  ◊ Hematological Complications and Treatment in COVID-19

CUTANEOUS DISEASE

GENE EDITING
  ◊ Gene editing CRISPR for the treatment of cutaneous disease

CYSTIC FIBROSIS

AIRWAY CELLS
  ◊ Benzo(c)quinolizinium compaunds

THERAPY WITH INHIBITORS
  ◊ Quorum Sensing Down-Regulation Counteracts the Negative Impact

GENE THERAPY
  ◊Genetic Therapies for Cystic Fibrosis
  ◊Potential of helper-dependent Adenoviral vectors in CRISPR-cas9-mediated lung gene therapy

  ◊Gene therapy approach for treating Cystic Fibrosis mutations through the usage of CRISPR prime editing
  ◊ In vivo correction of cystic fibrosis mediated by PNAs nanoparticles

THERAPY WITH CELLS
  ◊Therapy
  ◊ Generation of Induced Progenitor-like Cells from Mature Epithelial Cells